What is the recommended dosing, administration route, contraindications, and monitoring parameters for rasburicase in patients at high risk for tumor lysis syndrome?

Rasburicase for Tumor Lysis Syndrome

For high-risk patients, administer rasburicase 0.20 mg/kg/day (or 0.15-0.20 mg/kg/day) intravenously over 30 minutes, starting at least 4 hours before chemotherapy and continuing for 3-5 days, with dosing guided by uric acid levels. 1

Dosing Recommendations

Standard Dosing

• Dose: 0.20 mg/kg/day IV (FDA-approved range: 0.15-0.20 mg/kg) 2, 1
• Route: Intravenous infusion over 30 minutes 2, 1
• Duration: 3-5 days typically, though can range from 1-7 days based on uric acid control 2
• Timing: First dose at least 4 hours before starting tumor-specific therapy 1

Alternative Dosing Considerations

While guidelines recommend weight-based dosing, emerging research suggests single fixed doses (3-6 mg) may be effective in adults 3, 4, 5. However, prioritize guideline-recommended weight-based dosing as the standard approach, particularly for high-risk patients. The FDA label supports 0.15-0.20 mg/kg dosing 6.

Dosing Adjustments

• Massive tumor lysis: May require twice-daily administration 2
• Pediatric patients <2 years: May have higher uric acid exposure and lower response rates; monitor closely 6
• No renal dose adjustment required (unlike allopurinol) 2

Administration Route and Technique

• IV infusion only over 30 minutes in 50 mL normal saline 2
• Do NOT administer concomitantly with allopurinol - causes xanthine accumulation and removes substrate for rasburicase 1
• After completing rasburicase course, transition to oral allopurinol 1

Absolute Contraindications

Screen all patients before administration:

1. G6PD deficiency (most critical) - can cause life-threatening hemolysis 2, 1, 6

   • Higher risk in African American, Mediterranean, and Southeast Asian descent
   • Obtain thorough history of drug-induced hemolytic anemia
   • Perform definitive testing including RBC NADPH formation measurement 2

2. Known hypersensitivity/anaphylaxis to rasburicase or urate oxidase 2

3. History of methemoglobinemia 1

4. Pregnancy and lactation 6

   • Animal studies show fetal harm at 5× human exposure
   • Avoid breastfeeding during treatment and for 2 weeks after last dose 6

Relative Contraindications

• History of asthma or significant atopic allergy - limited experience, use with caution 2

Monitoring Parameters

Pre-Treatment Assessment

• Mandatory screening: G6PD status, creatinine clearance/eGFR, serum LDH 1
• Renal ultrasound in all patients undergoing chemotherapy 1

During High-Risk TLS Prevention

Monitor every 12 hours for first 3 days, then every 24 hours 1:

• Uric acid
• Electrolytes: potassium, phosphorus, calcium, sodium
• Renal function: creatinine, BUN
• LDH

During Active TLS Treatment

Monitor every 6 hours for first 24 hours, then daily 1:

• Vital signs (heart rate, blood pressure, urine output, respiratory rate)
• Serum uric acid
• Electrolytes (phosphate, calcium, potassium)
• Renal function (creatinine, BUN, urine pH, osmolality, specific gravity)
• Daily: CBC, LDH, albumin, serum osmolality, blood gases, ECG, body weight

Critical Monitoring Caveat

Uric acid samples must be placed immediately on ice and analyzed within 4 hours to prevent ex vivo enzymatic degradation by rasburicase, which causes falsely low readings 2, 6. This is a common pitfall that can lead to inappropriate dosing decisions.

Supportive Care Requirements

Hydration (Essential)

• Adults: Maintain urine output ≥100 mL/hour 1
• Children <10 kg: 3 mL/kg/hour 1
• Pediatric standard: 2-3 L/m²/day IV (200 mL/kg/day if <10 kg) 2
• Use loop diuretics if needed, except with obstructive uropathy or hypovolemia 1

Urine Alkalinization

Do NOT alkalinize urine in patients receiving rasburicase 1 - increases calcium phosphate precipitation and reduces xanthine solubility. This represents a shift from traditional TLS management.

Fluid Composition

• Initially withhold potassium, calcium, and phosphate from IV fluids due to TLS risks 2
• Maintain urine specific gravity at 1.010 2

Efficacy Expectations

• 97-99% of patients achieve uric acid normalization (<476 μmol/L or <8 mg/dL) within 4 hours of first dose 2, 3, 7
• 84% achieve undetectable levels (<0.7 mg/dL) 3
• Treatment duration guided by uric acid levels; discontinue when extremely low or undetectable 2

Adverse Events

Serious (Rare)

• Anaphylaxis (including fatal cases) 6
• Hemolysis (in G6PD deficiency)
• Methemoglobinemia 2, 6
• Seizures, respiratory distress, sepsis 2

Common

• Antibody formation (10% incidence) 2
• Fever, nausea, vomiting, headache, diarrhea 2

Clinical Pearls

• High-risk patients requiring rasburicase include those with: bulky disease, WBC >50,000/mm³, LDH >2× upper normal limit, pre-existing renal impairment, hyperuricemia (>8 mg/dL children, >10 mg/dL adults), high-grade lymphomas, or acute lymphoblastic leukemia 1

• Rasburicase allows earlier chemotherapy initiation compared to allopurinol due to rapid uric acid degradation 1

• For patients with preexisting hyperuricemia (≥7.5 mg/dL), rasburicase is preferred over allopurinol 2

• Inpatient setting recommended for high-risk patients receiving rasburicase 1